论文部分内容阅读
塞利洛尔(Celiprolol)是一种长效β_1选择性肾上腺素能拮抗剂,且伴有部分β_2拮抗剂作用和直接扩血管作用。作者重新评价了塞利洛尔作为心血管药物的作用。研究表明,β阻滞剂治疗动脉性高血压通常是安全的。但其发生血液动力学变化并具有许多副作用。然而,塞利洛尔具有特殊的药学特点,故对治疗高血压的裨益明显大于常规β阻滞剂。作者进行了多中心、双盲安慰、随机研究,评价了塞利洛尔治疗91例轻~中度动脉性高血压的疗效。结果表明,与安慰剂相比,治疗组患者直立位和仰卧位时
Celiprolol is a long-acting beta-1 selective adrenergic antagonist with a partial beta 2 antagonist effect and direct vasodilatation. The authors reevaluate the effect of celiprolol as a cardiovascular drug. Studies have shown that β blockers are generally safe for the treatment of arterial hypertension. But it has haemodynamic changes and has many side effects. However, the special pharmacological benefits of celiprolol are significantly greater for the treatment of hypertension than for conventional beta blockers. The authors conducted a multicenter, double-blind, comfort-based, randomized study to evaluate the efficacy of celiprolol in the treatment of 91 patients with mild to moderate arterial hypertension. The results showed that patients in the treatment group were upright and supine when compared with placebo